

Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

Anti-ARID1A antibody produced in rabbit

RRID:AB_1078205

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# HPA005456, RRID:AB_1078205

Antibody Information

URL: http://antibodyregistry.org/AB_1078205

Proper Citation: Sigma-Aldrich Cat# HPA005456, RRID:AB_1078205

Target Antigen: Human ARID1A

Host Organism: rabbit

Clonality: unknown

Comments: Vendor recommendations:

Antibody Name: Anti-ARID1A antibody produced in rabbit

Description: This unknown targets Human ARID1A

Target Organism: human

Antibody ID: AB_1078205

Vendor: Sigma-Aldrich

Catalog Number: HPA005456

Record Creation Time: 20231110T065112+0000

Record Last Update: 20260901T014949+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA005456>

No alerts have been found for Anti-ARID1A antibody produced in rabbit.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhu X, et al. (2026) Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1632.

Loe AKH, et al. (2026) ARID1A terminates gastric regeneration to prevent cancer. Developmental cell, 61(7), 1471.

Simões-Sousa S, et al. (2025) ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. Cell reports, 44(9), 116277.

Ngoi NYL, et al. (2025) Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3907.

Menon DU, et al. (2024) ARID1A governs the silencing of sex-linked transcription during male meiosis in the mouse. eLife, 12.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell.

Jana S, et al. (2023) Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. Cancer cell, 41(5), 853.

Celen C, et al. (2022) Arid1a loss potentiates pancreatic β -cell regeneration through activation of EGF signaling. Cell reports, 41(5), 111581.

Kao CH, et al. (2022) Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. Frontiers in immunology, 13, 1079253.

Blümli S, et al. (2021) Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription. Cell reports, 37(5), 109943.

Luo Q, et al. (2020) TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell reports, 30(1), 98.

Ogiwara H, et al. (2019) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. *Cancer cell*, 35(2), 177.

Li W, et al. (2019) A Homeostatic Arid1a-Dependent Permissive Chromatin State Licenses Hepatocyte Responsiveness to Liver-Injury-Associated YAP Signaling. *Cell stem cell*, 25(1), 54.

Ng PK, et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. *Cancer cell*, 33(3), 450.

Sun X, et al. (2017) Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. *Cancer cell*, 32(5), 574.

Howat W, et al. (2014) Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry. *F1000Research*, 3, 244.